Cargando…
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617914/ https://www.ncbi.nlm.nih.gov/pubmed/34834389 http://dx.doi.org/10.3390/pharmaceutics13111974 |
_version_ | 1784604621289816064 |
---|---|
author | Yin, Wen Xu, Tianqi Altai, Mohamed Oroujeni, Maryam Zhang, Jie Vorobyeva, Anzhelika Vorontsova, Olga Vtorushin, Sergey V. Tolmachev, Vladimir Gräslund, Torbjörn Orlova, Anna |
author_facet | Yin, Wen Xu, Tianqi Altai, Mohamed Oroujeni, Maryam Zhang, Jie Vorobyeva, Anzhelika Vorontsova, Olga Vtorushin, Sergey V. Tolmachev, Vladimir Gräslund, Torbjörn Orlova, Anna |
author_sort | Yin, Wen |
collection | PubMed |
description | Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1. |
format | Online Article Text |
id | pubmed-8617914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86179142021-11-27 The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy Yin, Wen Xu, Tianqi Altai, Mohamed Oroujeni, Maryam Zhang, Jie Vorobyeva, Anzhelika Vorontsova, Olga Vtorushin, Sergey V. Tolmachev, Vladimir Gräslund, Torbjörn Orlova, Anna Pharmaceutics Article Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1. MDPI 2021-11-21 /pmc/articles/PMC8617914/ /pubmed/34834389 http://dx.doi.org/10.3390/pharmaceutics13111974 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yin, Wen Xu, Tianqi Altai, Mohamed Oroujeni, Maryam Zhang, Jie Vorobyeva, Anzhelika Vorontsova, Olga Vtorushin, Sergey V. Tolmachev, Vladimir Gräslund, Torbjörn Orlova, Anna The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy |
title | The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy |
title_full | The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy |
title_fullStr | The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy |
title_full_unstemmed | The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy |
title_short | The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy |
title_sort | influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617914/ https://www.ncbi.nlm.nih.gov/pubmed/34834389 http://dx.doi.org/10.3390/pharmaceutics13111974 |
work_keys_str_mv | AT yinwen theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT xutianqi theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT altaimohamed theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT oroujenimaryam theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT zhangjie theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT vorobyevaanzhelika theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT vorontsovaolga theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT vtorushinsergeyv theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT tolmachevvladimir theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT graslundtorbjorn theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT orlovaanna theinfluenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT yinwen influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT xutianqi influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT altaimohamed influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT oroujenimaryam influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT zhangjie influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT vorobyevaanzhelika influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT vorontsovaolga influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT vtorushinsergeyv influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT tolmachevvladimir influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT graslundtorbjorn influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy AT orlovaanna influenceofdomainpermutationsofanalbuminbindingdomainfusedher2targetingaffibodybaseddrugconjugateontumorcellproliferationandtherapyefficacy |